Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Market outline PART 05: An overview of diseases treated using intravenous immunoglobulins PART 06: Market landscape • Market overview • Five forces analysis PART 07: Pipeline landscape PART 08: Market segmentation by Therapy area • Global intravenous immunoglobulins market by neurology • Global intravenous immunoglobins market for hematology • Global intravenous immunoglobins market for immunology • Global intravenous immunoglobins market for others PART 09: Geographical segmentation • Intravenous immunoglobulins market in Americas • Intravenous immunoglobulins market in EMEA • Intravenous immunoglobulins market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Market challenges PART 12: Market trends • Shift in manufacturing facilities to low-cost regions • Monetary support to plasma donors PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • CSL Behring • Grifols • Octapharma • Shire • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Major diseases treated using intravenous immunoglobins therapy Exhibit 02: Global intravenous immunoglobulins market snapshot Exhibit 03: Global intravenous immunoglobins market 2016-2021 ($ millions) Exhibit 04: Opportunity analysis in global intravenous immunoglobulins market Exhibit 05: Five forces analysis Exhibit 06: Pipeline analysis of vendors Exhibit 07: Key clinical trials 2016 Exhibit 08: Global intravenous immunoglobulin market by therapy area 2016 Exhibit 09: Global intravenous immunoglobins market for neurology 2016-2021 ($ million) Exhibit 10: Global intravenous immunoglobins market by hematology 2016-2021 ($ million) Exhibit 11: Global intravenous immunoglobins market for immunology 2016-2021 ($ million) Exhibit 12: Global intravenous immunoglobins market for others 2016-2021 ($ million) Exhibit 13: Global intravenous immunoglobulin market by geography 2016 and 2021 Exhibit 14: Global intravenous immunoglobulin market by geography 2016-2021 ($ millions) Exhibit 15: Market scenario in Americas Exhibit 16: Intravenous immunoglobulins market in Americas 2016-2021 ($ millions) Exhibit 17: North America: Percentage of global fractionation capacities 1999-2012 Exhibit 18: Market Scenario in EMEA Exhibit 19: Intravenous immunoglobulins market in EMEA 2016-2021 ($ million) Exhibit 20: Europe: percentage of global fractionation capacities 1999-2012 Exhibit 21: Market Scenario in APAC Exhibit 22: Intravenous immunoglobulins market in APAC 2016-2021 ($ million) Exhibit 23: APAC: Percentage of global fractionation capacities 1999-2012 Exhibit 24: Fractionation capacities of key vendors Exhibit 25: Factors contributing to overall cost of immunoglobulin production Exhibit 26: Various side-effects associated with immunoglobulin therapy Exhibit 27: Regulatory requirements for TGA approval Exhibit 28: Fractionating capacities globally 2007 and 2012 Exhibit 29: Competitive structure analysis of global intravenous immunoglobulins market 2016 Exhibit 30: Competitive factors in global intravenous immunoglobulins market Exhibit 31: Market penetration of manufacturers of intravenous immunoglobulins worldwide 2016 Exhibit 32: Strategic success factors of companies in global intravenous immunoglobulins market Exhibit 33: Key news in IVIG market Exhibit 34: CSL Behring: Key Highlights Exhibit 35: CSL Behring: Strength assessment Exhibit 36: CSL Behring: Strategy assessment Exhibit 37: CSL Behring: Opportunity assessment Exhibit 38: Grifols: Key highlights Exhibit 39: Grifols: Strength assessment Exhibit 40: Grifols: Strategy assessment Exhibit 41: Grifols: Opportunity assessment Exhibit 42: Octapharma: Key highlights Exhibit 43: Octapharma: Strength assessment Exhibit 44: Octapharma: Strategy assessment Exhibit 45: Octapharma: Opportunity assessment Exhibit 46: Shire: Key highlights Exhibit 47: Shire: Strength assessment Exhibit 48: Shire: Strategy assessment Exhibit 49: Shire: Opportunity assessment

CSL Behring, Grifols, Octapharma, Shire, ADMA Biologics, Bayer, Bharat Serum and Vaccines, Biotest AG, China Biologic Products, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, and Sanquin.